Full Press Release Details
Not For Promotional Use Disclaimer Certain information contained in this
presentation and statements made orally during Although we believe the expectations reflected in such forward-looking statements are this presentation relates to or is based on studies, publications, surveys and other data reasonable, we can give no
assurance that such expectations will prove to be correct. obtained from third-party sources and Verrica's own internal estimates and research. Accordingly, readers are cautioned not to place undue reliance on these forward- While Verrica
believes these third-party sources to be reliable as of the date of this looking statements. Except as required by applicable law, we do not plan to publicly presentation, it has not independently verified, and makes no representation as to the
update or revise any forward-looking statements contained herein, whether as a result adequacy, fairness, accuracy or completeness of, any information obtained from third- of any new information, future events, changed circumstances or otherwise. No
party sources. While Verrica believes its internal research is reliable, such research has representations or warranties (expressed or implied) are made about the accuracy of any not been verified by any independent source. such forward-looking
statements. The forward-looking statements in this presentation involve risks and uncertainties that could cause actual results to differ materially from This presentation contains forward-looking statements. Forward-looking statements are those
reflected in such statements. Risks and uncertainties that may cause actual results neither historical facts nor assurances of future performance. Instead, they are based on to differ materially include uncertainties inherent in the drug development
process and our current beliefs, expectations and assumptions regarding the future of our business, the regulatory approval process, our reliance on third parties over which we may not future plans and strategies, our clinical results and other
future conditions. All always have full control, and other risks and uncertainties that are described in our statements other than statements of historical facts contained in this presentation, Annual Report on Form 10-K for the year ended December
31, 2022 filed with the U.S. including statements regarding future results of operations and financial position, Securities and Exchange Commission (SEC) on March 6, 2023, our Quarterly Report on business strategy, the commercial launch of
YCANTH , including the timing thereof, and Form 10-Q for the quarter ended September 30, 2023 filed with SEC on November 9, the potential benefits of YCANTH and Verrica's product candidates to patients, degree 2023 and our other
filings made with the SEC. New risk factors and uncertainties may of market acceptance of approved products, research and development costs, current emerge from time to time, and it is not possible to predict all risk factors and and prospective
collaborations, timing and likelihood of success, plans and objectives of uncertainties. There can be no assurance that the opportunity will meet your investment management for future operations, future results of anticipated product candidates, and
objectives, that you will receive a return of all or part of such investment. Investment the potential payments and benefits to Verrica of the license agreement with Torii, are results may vary significantly over any given time period. The
appropriateness of a forward-looking statements. The words "may," "will," "should," "expect," "plan," particular investment or strategy will depend on an investor's individual circumstances
"anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," and objectives. We recommend that investors independently
evaluate specific "potential" or "continue" or the negative of these terms or other similar expressions are investments and strategies. intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. The information in this presentation, including without limitation the forward-looking statements contained herein, represent our views as of the date of this presentation. Copyright 2024 Verrica
Not For Promotional Use Now Approved: YCANTH - The First
Verrica is a dermatology therapeutics company developing medications for
skin diseases requiring medical intervention Focused on Clinician-Administered Reinventing Therapies and High Unmet dermatology Needs therapeutics with Focus on products with a focus on potential for development and reimbursement as a
Not For Promotional Use Our Product Candidate Portfolio: NEAR-TERM
CATALYSTS/ PRE-IND PHASE 2 PHASE 3 NDA EXPECTED MILESTONES NOW APPROVED Molluscum Contagiosum [a] Type C minutes received from FDA; Evaluating Common Warts timing of Phase 3 trial Evaluating timing of Phase External Genital Warts 3 trial Phase 2
Last Patient Dosed [b] December 23; Phase 2 Basal Cell Carcinoma results expected Q2 2024 [c] Initiate Phase 2 trial Plantar Warts [a] Type C meeting held with FDA held on clinical development plan for VP-102 Common Warts indication on
November 6, 2023. Meeting resulted in gaining alignment on the design of a pivotal Phase 3 development plan to evaluate VP-102/YCANTH for the treatment of Common Warts. [b] License excludes metastatic melanoma and metastatic Merkel cell
VP-103 VP-102 YCANTH
Not For Promotional Use Focused on Largest Unmet Needs in Dermatology
YCANTH VP-102 VP-315 NOW APPROVED PH3 READY PH2 IN-PROGRESS Molluscum Common Warts Nonmetastatic Skin Cancer (3) (1) (5) US Prevalence of ~22 million US Prevalence of ~6 million with US Prevalence of ~5.4M cases annually (2) (4) with ~1.5
million diagnosed annually ~1 million diagnosed annually Squamous cell carcinoma 1 1.8M 1.5M Patients 15% Diagnosed 1 Diagnosed 3.6M 85% 22M Annually 0.9 million Basal cell Prevalence Not Diagnosed carcinoma in U.S. 5.1 million (1) Prevalence in the
US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6). US Census estimates ~69.4MM children aged 0 to 16 years in 2016. (2) IQVIA projected dataset for 12 months ending October 2017 (3) IMS National Disease and
Therapeutic Index (NDTI) Rolling 5 Years Ending June 2016. Nguyen et al, Laser Treatment of Nongenital Verrucae A Systemic Review. JAMA Dermatology. 2016; 152(9): 1025-1033 (4) IQVIA Anonymous Longitudinal Patient Level Data (APLD) for 12 months
Not For Promotional Use Comprehensive Regulatory, IP and Manufacturing
Strategy to Maintain YCANTH Exclusivity; VP-315 COM-Issued Protection Patent applications on: 5 years of exclusivity for cantharidin as API Regulatory Extensive Issued and Pending Specific formulation potentially available upon
approval (potential for additional 6 months for Applicator Exclusivity; Patents Covering VP-315 pediatric exclusivity for common warts and Method of Use Patent Portfolio from 2029-2037 plantar warts indications) Design With
the approval of YCANTH , Verrica will, among other steps, petition PCT/EP2009/006774; composition-of-matter the FDA to have Cantharidin removed from 503B Category 1 as well as (COM) patent seek an Import Alert from the FDA to detain any
compounded Compounding *** Expires 2029 (EU) cantharidin before importation into the USA. Verrica will also enforce its Pharmacies rights to remove any compounded cantharidin that is essentially a copy Expires 2032 (US) of YCANTH
from the market unless it meets the FDA statutory Expires 2029 (Japan) exemptions.* YCANTH addresses stability Limited commercial CMOs PCT/EP2017/052279; methods-of-use patent, issues with standard with facilities for handling **
pending Manufacturing packaging and container/ highly potent and highly Expires 2037 (EU) closure systems flammable liquid products Expires 2037 (US) Expires 2037 (Japan) Unlikely to receive approval under an ANDA due to
uniqueness True Generic from patent pending protection and significant differences likely Unlikely between YCANTH and potential competitors * The FDA has the authority to regulate compounders. Improper compounding can result in monetary fines
plus felony convictions in case of repeat offenses and intent to fraud/mislead. ** Entered into a supply agreement for naturally-sourced cantharidin; subject to specified minimum annual purchase orders and forecasts, supplier agreed that it will not
France, Germany, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland and Turkey YCANTH VP-315
Not For Promotional Use Management Team with Extensive Product Launch
and Dermatology Experience Ted White Terry Kohler Gary Goldenberg, MD Joe Bonaccorso President & Chief Chief Financial Chief Commercial Chief Medical Executive Officer Officer Officer Officer Selected Launched Products Copyright 2024
Not For Promotional Use YCANTH (cantharidin) topical solution
Not For Promotional Use Molluscum Background Etiology and Clinical
Presentation TRANSMISSION Overview Skin to skin contact Sharing of contaminated objects Caused by a pox virus (e.g., clothing, towels, swimming pool toys) Primarily infects children, with the highest DIAGNOSIS &
SYMPTOMS incidence occurring in children <14 years old Typically 10 to 30 lesions Highly contagious 100+ lesions can be observed Lesions may be the only sign of infection and are often painless If
untreated, lesions persist an Can be diagnosed with skin average of 13 months, although in some biopsy to differentiate from people it can take up to five years other lesions Often leads to anxiety and social COMPLICATIONS challenges
for the patients and parents Skin irritation, inflammation, and re-infection and negatively impacts quality of life Follicular or papillary conjunctivitis if lesions on eyelids Cellulitis Copyright 2024 Verrica
Not For Promotional Use Current Treatments for DESCRIPTION LIMITATIONS
Molluscum are Not Pain and scarring Freezing the lesions FDA-Approved and Cryotherapy May be unsuitable for use in with liquid nitrogen children Have Many Limitations Using a curette or a surgical Pain and scarring instrument
with a scoop at Curettage Unsuitable for use in children Broad use limited by unproven the tip to scrape the lesions efficacy, scarring, lack of availability, safety concerns & pain Pain, cost and lack Applying a laser to
target of availability Laser Surgery and destroy the lesions Significantly undertreated patient Unsuitable for use in children population Applying various acids (e.g. salicylic acid), creams Unproven efficacy Topical Products
or blistering solutions to destroy the lesions Retinoids, antiviral Limited efficacy medicines, or immune Off-Label Drugs Side-effects modulating therapies Unproven efficacy Applying natural oils (e.g. tea tree oil) with
Not For Promotional Use YCANTH (cantharidin, 0.7%) Drug-device
Combination Product Delivered Via a Single-use Applicator DESIGNED FOR RELIABLE, AND TARGETED ADMINISTRATION Topical solution in a single-use applicator Active ingredient cantharidin (0.7%) in a proprietary topical formulation
Single-use applicator to reduce cross-contamination and facilitate application of the topical solution Small opening allows for targeting of affected skin GMP-controlled, shelf-stable, consistent topical formulation Allows for
reliable dosing/administration Oral deterrent to help mitigate the risk of accidental ingestion Cap Tip Filter Ampule Tube Visualization agent to identify treated lesions Copyright 2024 Verrica Pharmaceuticals. All rights
Not For Promotional Use Methods in two Phase 3 Trials, CAMP-1 &
CAMP-2, in Molluscum 1,2 Contagiosum YCANTH was studied in two randomized, double-blind, placebo-controlled phase 3 trials, Trial 1 and Trial 2 (n = 266, and n = 262, respectively) in subjects 2 years and older with molluscum wo identically
designed, contagiosum. randomized, double-blinded, multicenter, vehicle-controlled trials Most patients received a single 24-hour dermal administration of YCANTH or vehicle for each lesion every 3 weeks for up to 4 treatments. Primary
Endpoint Percent of participants with complete clearance of Molluscum contagiosum at Day 84 Safety & Tolerability Secondary Endpoint Percent of participants with complete clearance at Day 21, 42 and 63 If
severe local skin reactions occurred, YCANTH was removed prior to 24 hours after treatment. 1. Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product
Containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257-265 2. ClinicalTrials .gov (Trial 1 [NCT03377790] and Trial 2 [NCT03377803]) Copyright 2024 Verrica Pharmaceuticals. All rights
Not For Promotional Use Phase 3 Studies Demonstrated Favorable Activity
in Complete Clearance and Reducing Lesions Phase 3 Studies for Molluscum Demonstrate Statistically Significant Phase 3 Studies for Molluscum Demonstrate Statistically Significant Activity on Primary Endpoint of Percentage of Subjects with Complete
Activity Mean Percent Change in Molluscum Contagiosum Lesion Count Clearance of All Baseline and New Treatable MC lesions at Each Time from Baseline to Day 84 At Each Time Point (Pooled, ITT population) Point (Pooled, ITT population) Note: slide
reflects data from Phase 3 Molluscum Trials 1 and 2 (CAMP-1 and CAMP-2) Note: No statistical significance reported at Day 21 in CAMP-2. 1. Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating
Patients Achieving Complete Clearance Mean Percent Change (%)
Not For Promotional Use Application Site Adverse Reactions Leading to
Discontinuation of 1 Study Drug (Pooled, Safety Population) N (%) VP-102 Vehicle (N=311) (N=216) Application Site Vesicles 5 (1.6) 0 (0) Application Site Pain 3 (1.0) 0 (0) Application Site Pruritus 1 (0.3) 0 (0) Contact Dermatitis 1 (0.3) 0 (0)
Infection 1 (0.3) 0 (0) Gianotti-Crosti Syndrome* 0 (0) 1 (0.5) Total Discontinuation Rate 7 (2.3) 1 (0.5) Note: slide reflects pooled data from Phase 3 molluscum trials (CAMP-1 and CAMP-2) * Considered not related to treatment 1. Eichenfield LF,
Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257-265.
YCANTH (cantharidin) topical solution 0.7% Commercialization and
Not For Promotional Use Realizing the Molluscum Opportunity 15% US
PREVALENCE OF Diagnosed ~6 million in 0.9 million (1) molluscum US PREVALENCE WITH ~1 million (2) diagnosed annually 85% Not Diagnosed 5.1 million (1) Prevalence in the US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014
Not For Promotional Use Dermatologists are Familiar with Cantharidin
& Would Use if Available 87% ~70% Physicians who do not use Cantharidin stated Physicians reported they inaccessibility as a primary reason why they would use YCANTH if the cost of (1) (2) are not using the drug was covered (1) Pompei DT
et al. Cantharidin Therapy: Practice patterns and attitudes of health care providers. Journal of the American Academy of Dermatology. 2013; 68(6). Survey of 400 healthcare providers, 87.7% of responders were US based dermatologists. Copyright
Not For Promotional Use Physicians are Highly Favorable to
YCANTH Profile (1) Derms and Ped Derms KEY REASONS TO USE Efficacy Precise and pain free application 5.6 FDA approval Convenience of administration (1) Pediatricians Efficacy Fits into their current office model 6.3 Frustrated with not
treating and having no viable options Scale of 1 (unlikely to use at all) to 7 (highly likely to use) (1) Physician Qualitative research- one-hour individual interviews [n=30 Pediatricians, 13 Dermatologist, 5 Pediatric Dermatologists] Copyright
Not For Promotional Use Payer Research Suggests a 1,2 Favorable
Reimbursement Landscape Medical Directors, Pharmacy Directors, and IDN Stakeholders Research findings Payers recognize the unmet need for treatment of molluscum due to the lack of FDA approved The Payer Organizations and Plans therapies
represented in research Cover Based on market research and live meetings, we over 205 Mill aift on er Commercial & expect YCANTH to be predominantly covered Medicaid Lives under the medical benefit. YCANTH is an in- office
administered therapy More than 112 Million Lives Payers have indicated that being a medical Covered as of November 2023 benefit covered product, YCANTH will have lower rebates required for coverage 1. ArtSci Health Solution,
Not For Promotional Use Medical Benefit Advantages Over Pharmacy
Benefit Medical Benefit Pharmacy Benefit Reimbursement for products More common Less common administered in office by HCP Reimbursed upon launch, More common Less common prior to clinical review Subject to rebates and discounts in order to obtain
Less common More common formulary access Typically, higher deductions to meet rebate Gross-to-Net Deductions Typically, lower deductions than Pharmacy Benefit demands and costs of co-pay program Review cycle timing Shorter review cycle Longer review
Not For Promotional Use Integrated Commercial Approach with Multiple
Strategic Levers COMMERCIAL STRATEGY Brand KOL Specialized Dedicated Buy-and-Bill / Awareness Engagement Sales Team Institutional Team Specialty Pharmacy Drive YCANTH Established relationships Targeting office-based Specialists to promote to
Forward Deployed awareness through with industry leading and institutional dermatologists in academic Inventory Available cost-efficient HCP and Key Opinion Leaders Dermatologists, and settings and group practices Supportive consumer advertising
Not For Promotional Use 53 office-based representatives (from 50 at
YCANTH Launched in launch) targeting ~9K HCPs September 2023 with reps Q1 '24 expansion to 8 dedicated institutional targeting primarily representatives (from 5 at launch) focusing on the most important ~90 Health Systems Pediatric
Dermatologists Q1 24 expansion to 20 dedicated pediatric account and Dermatologists managers (from 5 at launch) focusing on members of pediatric buying group and select other large groups. 5 field relations managers providing billing and
Not For Promotional Use Physicians will have a choice of Distribution
Model Buy-and-Bill Specialty Pharmacy HCP Reimbursement Yes (within 1-2 quarters post-launch); Permanent J-code Reimbursed under miscellaneous J-code No until permanent J-code assigned Office visit fee Yes Yes Lesion destruction Yes Yes (CPT 17110,
17111) Yes, typically 6%-10% of ASP Margin on sale of product No (dependent on health plan) Distribution Opportunity for Forward Deployed Inventory Specialty Pharmacy Model Verrica sells product to distributor RX filled by specialty
pharmacy Shelf-stable; no cold storage requirements The pharmacy will also support prior-authorizations, if applicable Physicians purchase product in traditional buy and bill model or can elect to receive "forward